All In Biotech

Drug Trial Radar · NCT04222972

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 223 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

223

Actual

Start

Jul 24, 2020

Primary completion

Jan 27, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.

Conditions

  • RET-fusion Non Small Cell Lung Cancer
  • Lung Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Disease
  • Carcinoma, Bronchogenic
  • Bronchial Diseases
  • Head and Neck Neoplasms
  • Adenocarcinoma
  • Carcinoma
  • Neoplasms by Histologic Type
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Nerve Tissue

Interventions

  • PralsetinibDrug

    Administered orally

  • CarboplatinDrug

    Administered IV

  • CisplatinDrug

    Administered IV

  • PemetrexedDrug

    Administered IV

  • PembrolizumabDrug

    Administered IV

  • GemcitabineDrug

    Administered IV

  • PaclitaxelDrug

    Administered IV

  • Nab-PaclitaxelDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)Time frame: Up to approximately 50 months

Locations

74 sites in 22 countries. Site status is shown where the registry gives one.

  • Hospital Britanico

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • UZ Antwerpen

    Edegem, Belgium

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital A. C. Camargo

    São Paulo, São Paulo, Brazil

  • Clinica CIMCA

    San José, Costa Rica

  • Institut Bergonie CLCC Bordeaux

    Bordeaux, France

  • Hôpital Ambroise Paré - Boulogne-Billancourt

    Boulogne-Billancourt, France

  • Hôpital Louis Pradel, Hospices Civils de Lyon

    Bron, France

  • CHRU Lille Service de Pneumologie et Oncologie Thoracique

    Lille, France

  • Institut Paoli Calmettes

    Marseille, France

  • Hopital Bichat Claude Bernard

    Paris, France

  • Hopital Tenon

    Paris, France

  • Hopital de Pontchaillou

    Rennes, France

  • Ico Rene Gauducheau

    Saint-Herblain, France

  • CHU Strasbourg - Nouvel Hopital Civil

    Strasbourg, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitätsklinikum Carl Gustav Carus, Medizinische Klinik I, Pneumologie MK1-A13

    Dresden, Germany

  • Asklepios-Fachkliniken Muenchen-Gauting

    Gauting, Germany

  • Pius-Hospital

    Oldenburg, Germany

  • Leopoldina-Krankenhaus Medizinische Klinik II

    Schweinfurt, Germany

  • Klinik Schillerhöhe

    Stuttgart, Germany

  • St. James Hospital

    Dublin, Ireland

  • Ospedale Clinicizzato SS Annunziata

    Chieti, Abruzzo, Italy

  • IRCCS Giovanni Paolo II Istituto Oncologico

    Bari, Apulia, Italy

  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale

    Naples, Campania, Italy

  • Ospedale Provinciale Santa Maria Delle Croci

    Ravenna, Emilia-Romagna, Italy

  • Istituto Nazionale Tumori Regina Elena

    Rome, Lazio, Italy

  • AZ. Ospedaliera San Giovanni - Addolorata

    Rome, Lazio, Italy

  • Irccs Ospedale San Raffaele

    Milan, Lombardy, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, Italy

  • Istituto Europeo Di Oncologia

    Milan, Lombardy, Italy

  • Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello

    Pisa, Tuscany, Italy

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, Italy

  • A.O.U. INTEGRATA DI VERONA-Ospedale Civile Maggiore Borgo Trento

    Verona, Veneto, Italy

  • Kyushu University Hospital

    Fukuoka, Japan

  • National Hospital Organization Himeji Medical Center

    Hyōgo, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.